After infusion of CD22 and CD19 CAR-T cells, all of 4 patients with R/R B-ALL achieved minimal residual diseade (MRD)-negative CR, which demonstrated the safety and efficiency of sequentially combined CD22 CAR-T and CD19 CAR-T cell therapy. This evidence concerns the gene CD22 and acute lymphoblastic leukemia.